ArticleFrontiers in immunology2026
Differences in immune indicators among normal, high-risk, and esophageal cancer populations and development of a predictive model.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically compare the differences in immune characteristics among three populations (normal group, high-risk group, and esophageal cancer [EC] patients group) and construct a predictive model based on immune metrics, thereby exploring its value in EC risk assessment and early diagnosis. Methods: A total of 440 participants were enrolled, including 173 normal individuals, 162 high-risk individuals, and 105 EC patients. Peripheral blood samples were collected, and 75 immune metrics were detected using flow cytometry. First, 21 highly correlated indicators were eliminated through the Pearson correlation matrix (|r|≥0.7), leaving 54 indicators for further analysis. Multivariate analysis of variance (MANOVA) was used to assess the effect of EC grouping on immune metrics, adjusting for gender and age. Significant indicators were analyzed using analysis of covariance (ANCOVA) and the false discovery rate (FDR). Stratified sensitivity analysis was conducted to verify the robustness of the results. Finally, a predictive model was built using 12 key immune metrics, and 10 covariates. The model performance was evaluated by 10-fold cross-validation, neural network algorithm, accuracy, Kappa value, and area under the receiver operating characteristic curve (AUC). Results: MANOVA showed that EC grouping had a significant overall impact on the 54-immune metrics (Pillai = 0.585, Conclusion: This study demonstrates distinct and stable immune profiles across EC risk groups. The immune-based machine learning model effectively differentiates normal, high-risk, and cancer populations, offering a promising non-invasive tool for early risk assessment and screening of esophageal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.